Generate BiomedicinesGENB
Recorded

Generate Biomedicines 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration50 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Good to get started here. Thanks, everybody, for joining us. We have made it to the afternoon of day one of the Guggenheim Healthcare Innovation Conference. It is 2026, and we are all looking forward to more great company data ahead. Thrilled to have Generate Biomedicines with us here today. CEO Mike Nally, President and CFO Jason Silvers, to my left sequentially. Earlier this year, the company came public via a $400 million IPO in February 2026. A lot of progress along the way. Mike, I will just turn it over to you to maybe give us the lay of the land of where Generate sits today, what you are seeking to accomplish in the next 12-18 months, and then beyond.

Michael NallyCEO

Yeah. First and foremost, thanks, Seamus, for the opportunity. It is always great to be here. It has been really fun being at Generate. I have now been at Generate almost six years after having spent 18 years at Merck, and when I joined the company, it was going after a premise that nobody in the world believed in, that generative AI could actually design protein therapeutics. At that time, when I joined, there were no pipeline programs at all. What we have been able to see over the past five-plus years is not only does the technology work, but it translates really, really quickly. Our first asset, our lead asset is now in phase III of development. It is going after severe asthma. The early data is suggestive that it will be dosed every six months.

Michael NallyCEO

It reduces key biomarkers at least as well, if not better, than what we saw with tezepelumab. We are really encouraged by not only the state of the technology, but also its ability to translate into meaningful therapeutics. We have now put five molecules into the clinic. Behind our asthma drug is, there are a couple of oncology assets that I am sure we will talk more about. I think what is really exciting for us is, we are just scratching the surface of the potential of this sort of a technology. While I think there is a lot of noise in this kind of tech bio intersection with some people saying, "We are going to cure cancer in five years," others saying, "It is not going to have any impact," inevitably, the answer sits certainly well in between.

Michael NallyCEO

We are on the more optimistic side, and we are already starting to see the very tangible markers that these technologies are helping us understand biology in really extraordinary ways, and I think we are just at the early days of the impact.

Speaker

Right. So maybe talk about your first program. I think you've taken a bold approach to the development. A lot of folks would say that it was a risky approach. Our view is that few answers, few incremental answers could have been gained by running a phase II here. So, can you just help us understand what brought you to phase III so quickly with the SOLAIRIA program?

Michael NallyCEO

Yeah. Well, I think, Seamus, this concept of risk, we're in a high-risk business, right? 95% of things fail when you start a program. We thought this was a really sound bet, and we still, to this day, our conviction in that bet has only grown. Our choice to skip phase II was predicated on a series of very measurable facts. We know we bind the same epitope as tezepelumab. We know in the phase I trial, we saw the same or better biomarker reduction as tezepelumab on highly correlative biomarkers, including EOS, FeNO, IL-5, IL-13. We know there was a regulatory precedent for pursuing this sort of pathway. Depemokimab has been approved in both the U.S. and the EU using this sort of an approach.

Michael NallyCEO

We know based on our modeling that our target engagement is at the same level or better than tezepelumab at every time point, so 99.9% target engagement.

Speaker

Yeah. So, the leap that we made was with that body of evidence, we could effectively select the dose using the phase I data.

Michael NallyCEO

And the other thing that was very evident in the data was that you saw no additional biomarker reductions when you dose beyond the 300 milligrams that we've ultimately selected.

Speaker

Yeah. For us, if you go back and look at the tezepelumab phase II dose-finding study, they studied three doses.

Michael NallyCEO

There was an eight-fold difference in dose, and they showed no statistically significant difference in asthma exacerbation rates.

Speaker

Yeah. You would ultimately make a pragmatic choice.

Michael NallyCEO

You'll spend $50 million and take two years, or you just make the dose selection choice based on the evidence that you have.

Speaker

Yeah. For us, this was clearly the opportunity was obviously a lot more sizable if we were the first long-acting to make it to the market.

Michael NallyCEO

We think we have the best-in-class candidate given both the half-life and the biophysical characteristics, and we think the dosing data actually was pretty robust when you actually look at it.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day